Market Valuation & Earnings Multiples
Market capitalization, P/E ratios, and enterprise value
Market Cap2.42B
Enterprise Value2.44B
Trailing P/E8.10
Forward P/E4.06
AUPH
(NASDAQ)Aurinia Pharmaceuticals Inc.
$17.55-- (--)
Loading... - Market loading
Aurinia Pharmaceuticals (AUPH) Key Statistics & Financial Metrics
Complete stock analysis with 40+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.
Stock Valuation Metrics
Market value, earnings multiples, and pricing ratios
Price-Based Ratios
Valuation ratios based on stock price
Price/Sales (ttm)8.10
Forward Price/Sales6.71
Price/Book (mrq)4.26
Price/Tangible Book (mrq)4.28
Price/FCF (ttm)14.59
Price/OCF (ttm)14.57
Enterprise Value Ratios
EV-based valuation multiples
EV/Revenue8.19
EV/Earnings8.19
EV/EBITDA15.30
EV/EBIT22.52
EV/FCF14.76
Stock Price
Current price, 52-week range, and moving averages
Current Price$17.55
1-Day Change-5.75%
52-Week High$19.25
52-Week Low$7.29
52-Week Change118.56%
YTD Change14.33%
1-Year Change103.36%
50-Day MA$15.94
200-Day MA$14.69
Avg Volume (30 day)1.40M
Share Statistics
Outstanding shares, float, and per-share metrics
Shares Outstanding137.64M
Book Value per Share$4.12
Net Cash per Share$-0.20
FCF per Share$1.20
Analyst Price Targets & Consensus
Wall Street analyst ratings and 12-month price targets (90 days)
Price Target$15.67
Target Upside/Downside-10.71%
Analyst ConsensusHold
Analyst Count3
Profitability & Financial Performance
Profit margins, return metrics, and earnings analysis
Profit Margins
Profitability margins across income statement
Gross Margin89.85%
EBITDA Margin (ttm)53.54%
EBIT Margin (ttm)36.37%
Operating Margin (ttm)41.73%
Pretax Margin (ttm)44.83%
Profit Margin (ttm)99.97%
FCF Margin (ttm)55.50%
Return on Investment Metrics
ROE, ROA, ROIC, and capital efficiency ratios
Return on Equity (ttm)52.54%
Return on Assets (ttm)41.19%
Return on Invested Capital (ttm)18.22%
Return on Capital Employed (ttm)17.02%
Income Statement (TTM)
Trailing twelve months revenue and earnings
Revenue298.30M
Gross Profit268.03M
Operating Income124.49M
Pretax Income133.73M
Net Income298.21M
EBITDA159.69M
EBIT108.48M
Diluted EPS$2.16
Cash Flow (TTM)
Operating cash flow and free cash flow metrics
Operating Cash Flow165.82M
Capital Expenditures271.76K
Free Cash Flow165.55M
Growth Rates (YoY)
Year-over-year growth metrics
Revenue Growth20.62%
Financial Health & Dividends
Balance sheet analysis, debt ratios, and dividend metrics
Assets & Cash
Total assets and cash positions
Total Assets (mrq)724.00M
Cash & Securities (mrq)41.01M
Net Cash (mrq)-27.63M
Net Cash per Share$-0.20
Debt & Liabilities
Liabilities, debt, equity, and working capital
Total Debt (mrq)68.64M
Working Capital (mrq)393.69M
Total Equity (mrq)567.63M
Book Value per Share$4.12
Liquidity & Leverage
Liquidity, leverage, and debt coverage ratios
Current Ratio (mrq)5.55
Quick Ratio (mrq)5.01
Debt/Equity (mrq)0.12
Debt/EBITDA (ttm)0.43
Debt/FCF (ttm)0.41
Dividend History & Payout Analysis
Dividend yield, payout ratios, and growth metrics
Dividend per Share (TTM)$0.00
Dividend Yield0.00%
Payout Ratio (Earnings)0.00%
Yield Metrics
Earnings, FCF, buyback, and shareholder yields
Earnings Yield12.35%
FCF Yield6.85%
Buyback Yield3.57%
Total Shareholder Yield3.57%
Financial Health Scores
Risk assessment and quality metrics
Altman Z-Score5.62
Piotroski F-Score7/9
Fair Value & Intrinsic Value
Lynch fair value, Graham number, and valuation models
Graham Number$14.15
Graham Upside/Downside-19.35%
Frequently Asked Questions About Aurinia Pharmaceuticals Statistics
What are the key financial metrics for AUPH?
Aurinia Pharmaceuticals Inc. (AUPH) statistics include 40+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.
What is AUPH's valuation analysis?
The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether Aurinia Pharmaceuticals is overvalued or undervalued.
How do I read AUPH's profitability ratios?
Aurinia Pharmaceuticals's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.
What do AUPH's debt ratios indicate?
The financial health section shows Aurinia Pharmaceuticals's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.
What is AUPH's dividend analysis?
The dividend section covers Aurinia Pharmaceuticals's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.